These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35246560)

  • 1. Waning of SARS-CoV-2 booster viral-load reduction effectiveness.
    Levine-Tiefenbrun M; Yelin I; Alapi H; Herzel E; Kuint J; Chodick G; Gazit S; Patalon T; Kishony R
    Nat Commun; 2022 Mar; 13(1):1237. PubMed ID: 35246560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Levine-Tiefenbrun M; Yelin I; Alapi H; Katz R; Herzel E; Kuint J; Chodick G; Gazit S; Patalon T; Kishony R
    Nat Med; 2021 Dec; 27(12):2108-2110. PubMed ID: 34728830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
    Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 vaccine breakthrough infections.
    Gupta RK; Topol EJ
    Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Audio Interview: Waning Immunity against SARS-CoV-2.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(24):e99. PubMed ID: 34879456
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
    Jalkanen P; Kolehmainen P; Häkkinen HK; Huttunen M; Tähtinen PA; Lundberg R; Maljanen S; Reinholm A; Tauriainen S; Pakkanen SH; Levonen I; Nousiainen A; Miller T; Välimaa H; Ivaska L; Pasternack A; Naves R; Ritvos O; Österlund P; Kuivanen S; Smura T; Hepojoki J; Vapalahti O; Lempainen J; Kakkola L; Kantele A; Julkunen I
    Nat Commun; 2021 Jun; 12(1):3991. PubMed ID: 34183681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load.
    Migueres M; Dimeglio C; Trémeaux P; Raymond S; Lhomme S; Da Silva I; Oliveira Mendes K; Abravanel F; Félicé MP; Mansuy JM; Izopet J
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
    Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Pérez Potti A; Rivera Ballesteros O; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Loré K; Sobkowiak MJ; Gabarrini G; Healy K; Sällberg Chen M; Alici E; Björkström NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren HG
    Mol Med; 2022 Feb; 28(1):20. PubMed ID: 35135470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
    N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
    [No Abstract]   [Full Text] [Related]  

  • 11. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
    Servellita V; Morris MK; Sotomayor-Gonzalez A; Gliwa AS; Torres E; Brazer N; Zhou A; Hernandez KT; Sankaran M; Wang B; Wong D; Wang C; Zhang Y; Reyes KR; Glasner D; Deng X; Streithorst J; Miller S; Frias E; Rodgers M; Cloherty G; Hackett J; Hanson C; Wadford D; Philip S; Topper S; Sachdev D; Chiu CY
    Nat Microbiol; 2022 Feb; 7(2):277-288. PubMed ID: 35013591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waning Immunity after the BNT162b2 Vaccine in Israel.
    Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Haas EJ; Milo R; Alroy-Preis S; Ash N; Huppert A
    N Engl J Med; 2021 Dec; 385(24):e85. PubMed ID: 34706170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
    Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
    Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence.
    Daungsupawong H; Wiwanitkit V
    Semergen; 2024; 50(4):102132. PubMed ID: 38295632
    [No Abstract]   [Full Text] [Related]  

  • 16. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do health-care workers need a COVID-19 vaccine booster?
    Cirillo N
    Lancet Infect Dis; 2022 Jan; 22(1):20. PubMed ID: 34953546
    [No Abstract]   [Full Text] [Related]  

  • 18. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
    Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
    [No Abstract]   [Full Text] [Related]  

  • 19. Three, four or more: what's the magic number for booster shots?
    Watson C
    Nature; 2022 Feb; 602(7895):17-18. PubMed ID: 35091715
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
    Levine-Tiefenbrun M; Yelin I; Katz R; Herzel E; Golan Z; Schreiber L; Wolf T; Nadler V; Ben-Tov A; Kuint J; Gazit S; Patalon T; Chodick G; Kishony R
    Nat Med; 2021 May; 27(5):790-792. PubMed ID: 33782619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.